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The overall goal for any commercial 
organization involved in the develop-
ment of microbial organisms for agri-
cultural, forestry, or vector control ap-
plications is profitability. Whether or 
not we agrée with this perspective, it 
forms the core of our capitalist indus-
trial System. The agricultural world is 
littered with the débris from commer-
cial biocontrol product failures over the 
last twenty-five years. As described at 
previous professional meetings, there 
is a véritable "graveyard" of microbial 
product failures and ail were ultimately 
linked to the inability to generate a 
consistent, profitable, product. 
Once we accept the tenet of profit-
ability as a key success factor for any 
organization involved in the commer-
cial development of microbial organ-
isms, we can stretch our thoughts to an 
assessment of the fundamental drivers 
impacting the commercial process. 
Without doubt, research and develop-
ment are the basis for any successful 
microbial product. However, we pres-
ently exist in one of the most highly 
regulated industries, and as such, a large 
portion of current research and devel-
opment is dedicated to meeting the 
numerous regulatory demands for any 
new product (organism). Theoneword 
that we must embrace, if microbial 
products are to find a niche in the future 
agricultural world, is "flexibility". Flex-
ibility will be key to the registration of 
current and future products. If we are 
not willing to adapt to the individual 
characteristics of thèse products, then 
the future of microbiais is almost cer-
tainly limited, if not eliminated entirely. 
We presently face a number of issues 
beginning with the acceptance of mi-
crobial products as totally différent from 
the classical chemical alternatives for 
which régulations were and still are 
primarily written and directed. Bacte-
ria, fungi, viruses, protozoa, etc. are so 
distinctly différent from each other that 
a common denominatorfor registration 
of thèse organisms is difficult to iden-
tify. As a resuit, this leads to difficult 
décisions when trying to express the 
active ingrédient, spécifie activity, or 
formulation potency for product label-
ing. We are still grasping for the final 
understanding of how Bt works after 
thirty plus years of research. We can 
not afford to make a similar investment 
of resources for ail the other microbial 
candidates. 
The regulatory issues do not stop with 
identification of potency for a commer-
cial label. We are also dealing with a 
number of additional labeling issues, 
such as spray drift, worker reentry in-
tervais, and container disposai, ail of 
which are most likely of critical impor-
tance for hazardous chemical products, 
but less likely to be problems for micro-
bial products. If we are trying to en-
courage the use of microbial products, 
then we must adapt label requirements 
for thèse factors to promote their sélec-
tion and use. Thèse factors can be 
critical in today's forestry and vector 
(mosquito) control programs. Twenty 
36 
years of expérience in applications to 
forests and aquatic Systems with mi-
crobial products should provide valu-
able insight to "acute and chronic" 
exposure that must not be overlooked. 
The same alarmist issues that are raised 
today as "concerns" are not any différ-
ent than what was elevated within and 
outside the scientific community in the 
1970's. To our overall benefit, the 
"Andromeda strain" has not become a 
reality, or else the world would hâve 
been consumed by Bt or some other 
microbial product. 
It may be difficult to détermine if 
regulatory is the primary or secondary 
driver, but if it is not the first then prod-
uct "efficacy" surely is the most critical 
driver. Today's farmer and future ag-
ricultural producers are provided with a 
buffet of alternatives for the control of 
problem pests (weeds, insects, plant 
diseases, etc.). To the greater extent, 
the majority of thèse options are highly 
effective products. As a resuit, the 
commercial grower has corne to expect 
relatively few problems during the grow-
ing cycle of a particular crop. We may 
not be able to control the weather, but 
we can control the soil fertility, weeds, 
insects, and diseases that can adverse-
ly affect a grower's yield. Let's accept 
the fact that the typical grower is com-
pensated for yield and in certain cases 
a high quality yield. Unless we can 
provide the grower with an efficacious 
microbial alternative to the currently 
available and usually reliable synthetic 
chemical products, then we are ultimate-
ly foreshadowing failure. We hâve his-
torically failed to develop microbial 
products that are équivalent or superi-
or to synthetic chemistry. This must 
change. 
The third driver is primarily controlled 
by the commercial organization in-
volved in the development of any mi-
crobial product. The driver is large scale 
production which eventually translates 
directly into the final product cost. Why 
are production and cost so important? 
Can cost be more important than safety 
concerns? The answer is simply that 
the grower is confronted with the same 
profitability motives that the commer-
cial organization faces. If the grower 
can not produce a crop in a cost effec-
tive manner, then his future is certainly 
limited. As a resuit, the grower will 
generally accept the least expensive, 
effective option to control any problem 
that is encountered during the growing 
cycle of that crop. Unless there are 
significant financial rewards provided 
directly to the individual grower for the 
sélection of less hazardous approaches 
or products, the grower will always 
default to the most cost effective op-
tion. This is not just human nature, but 
financial survival. With the exception 
of bacterial-based products, we hâve 
failed to develop cost effective produc-
tion technology for the majority of 
microbial product candidates. 
The net effect of thèse drivers can be 
summarized in one word, "expedien-
cy". Time is money and time becomes 
a key financial driver. However, what 
are the many factors that hâve impact-
ed and continue to impact time or ex-
pediency in the development of micro-
bial products? 
We hâve already identified efficacy 
as a key objective for research and 
development programs. However, one 
of the key shortcomings for ail micro-
bial products has been the failure to 
develop a long term (>2 year) stability 
profile for formulated commercial prod-
ucts. With the exception of Bt formu-
lations, the majority of ail microbial 
products are not viable for six months 
at room température storage conditions. 
This is a significant weakness that must 
be overcome if thèse products are to 
become acceptable optionsforthe com-
mercial grower. Widescale acceptance 
and global use of any product requires 
transportation, handling, and exposure 
to environmental extrêmes. What works 
in North America must also work in 
equatorial Africa. 
Although we ail acknowledge that one 
of our long term objectives is the pro-
tection of the overall environment, we 
must also accept the fact that the cost 
of évaluation of microbial products and 
their impact on similar ecosystems has 
become excessively expensive. For 
example, ecozone évaluations hâve 
been conducted with Bt products used 
for forest and vector control programs 
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on a global scale, and frankly at an 
unacceptable cost in terms of time and 
money. There is some point when we 
must learn to accept the results gener-
ated from our guideline studies that 
hâve been identified for registration 
and not embark on or acquiesce to the 
"search for the Holy Grail approach" to 
environ m entai monitoring and assess-
ment. Almost every nation appears to 
hâve developed a set of spécifie param-
eters to détermine environmental ac-
ceptability. Unfortunately, few are the 
same. This will soon become financial-
ly untenable to manufacturers, if that 
time has not already arrived. If "har-
monization" of thèse ecotoxicology and 
environmental requirements is the so-
lution, then it is long overdue. The 
critical issue with microbiais has not 
been safety related. We must shift our 
near and long term focus to the key 
drivers. 
Human safety has been and should 
be the first priority for the évaluation 
and development of any microbial prod-
uct. But, again we hâve taken scientific 
curiosity to extrêmes, with a good ex-
ample being the current issue and de-
bate surrounding enterotoxins and 
bacterial microbial products. Since 
many species can be significantly sim-
ilar genetically, but at the same time 
physiologically and phenotypically dif-
férent, then it is probable that two close-
ly related bacterial species can also be 
substantially différent. Although Bt 
manufacturers (registrants) hâve been 
required to complète a number of mam-
malian enterotoxin évaluations (rabbit 
ileal loop assay, monkey feeding study) 
in order to attain product registration, 
there is still a movement to create ad-
ditional testing to further evaluate en-
terotoxins. This assault also fails to 
recognize the years of exposure of 
humans to Bt, not only indirectly from 
soil exposure, but also directly on a 
number of food crops. At some point 
in time, we must accept the fact that 
"more is not always better" when it 
cornes toadditional testing. From 1996-
1997 the résidents of Auckland, New 
Zealand were exposed to more than 
forty successive sprays of Btk as a re-
suit of an urban forest insect eradica-
tion program. Outside of some "alarm-
ist" complaints, the overall consensus 
from the Auckland Health officiais indi-
cated and reinforced the outstanding 
safety record of Btk products. When 
will we consider historical or corroba-
tive évidence as an important factor in 
our final décision making process? 
Microbial agents offer us another 
potential option for addressing the 
development of pest résistance on a 
global scale. Although microbial prod-
ucts may not be the complète answer, 
bacterial, fungal, and viral organisms 
offer diverse alternatives to classical 
synthetic chemistry. There is also a 
veryfine lineseparatingthe use of thèse 
"active ingrédients" as gène spécifie 
transformations in a number of agricul-
turally important crops and the poten-
tial loss of thèse agents due to the 
development of pest résistance. Athor-
ough understanding of the implications 
of widespread résistance development 
to microbial products should be a re-
search priority. However, this effort 
would be most effectively coordinated 
by an independent organization with 
broad-reaching authority. For a variety 
of reasons, most commercial organiza-
tions are severely limited in their ability 
to conduct "résistance directed" re-
search under field conditions. 
So where does that leave us today? 
We need to concentrate our research 
and development efforts on: 1) improv-
ing microbial product performance 
(efficacy); 2) identifying more cost-
effective production technology for ail 
microbiais; 3) develop improved shelf-
life (formulation stability >2 years at 
RT); 4) identify more active "strains and 
toxins" to keep pace with the everchang-
ing performance benchmarks; 5) en-
hance "residual" efficacy or perfor-
mance to mirror current alternatives. 
We must understand that microbial 
biocontrol agents will continue to face 
compétition from transgenic plants and 
new pesticide chemistry, as well as other 
future technology. In biology and the 
business world, Darwinian principles 
will prevail. 
Finally, we must be flexible and ex-
ercise significant doses of "common 
sensé" when we are faced with chal-
lenges to a microbial regulatory System 
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that has produced an outstanding record 
of human, animal, and environmental 
protection to the public for more than 
twenty years. There must be a point 
when more is not better and we must 
be willing to embrace that position. 
KEY QUESTIONS/ISSUES 
FOR DISCUSSION 
1. How can we develop flexibility in the 
regulatory labeling processto résolve 
issues concerning microbial poten-
cy, active ingrédient, spécifie activity, 
spray drift, worker re-entry, etc. with-
out the investment of significant com-
mercial research resources? 
2. Are the recommendations for addi-
tional safety research (e.g. microbial 
enterotoxins, ecozones) based on real 
scientific concerns or on socio-eco-
nomic or political issues? 
3. How can we stimulate spécifie re-
search for the development of new 
production and formulation technol-
ogy for microbial agents that will 
address the current weaknesses? 
4. How can we encourage novel ap-
proaches to the identification of new 
microbial agents with the perfor-
mance (efficacy) potential to replace 
existing products? 
5. Can we utilize a permanent biparti-
san committee comprised of aca-
démie, government, and industry 
members as a "sounding board" to 
address spécifie issues related to mi-
crobial product registration (e.g. en-
terotoxins, daphnia study require-
ments)? 
6. How can we utilize some of the his-
torical expérience and évidence to 
educate the gênerai public about the 
acceptability of microbial control 
agents for agricultural, forestry, and 
environmental health applications? 
7. What can be done to eliminate the 
political boundaries that interfère with 
the harmonization of microbial regis-
tration guidelines? 
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